Skip to main content

The Journal Gazette

Friday, November 09, 2018 1:00 am

Briefs

Tesla taps woman as board chair

Staff, news services

DETROIT – Australian telecommunications executive Robyn Denholm brings much-needed financial and auto industry expertise to her new role as Tesla's board chairwoman, but her biggest challenge is whether she can rein in a CEO with a proclivity for misbehavior.

Denholm, who has been a Tesla board member for nearly five years, was named to the post late Wednesday, replacing Elon Musk as part of a securities fraud settlement with U.S. government regulators.

Corporate governance experts say they would have preferred an outsider with manufacturing expertise be appointed to lead the board, now dominated by people with personal and financial ties to Musk, including his brother.

BUILD program to honor 8 graduates

The Northeast Indiana Building Trades, Fort Wayne Urban League, Indiana Plan, Northeast Indiana Works, Ivy Tech and the city of Fort Wayne will celebrate an eight-person graduating class of the BUILD program today.

BUILD, or Building Trades, Urban League, Indiana Plan, Local and Diversity, is a free, four-week pre-apprenticeship training program that prepares participants for a career in the skilled trades. The program is designed to assist people in being job ready, as well as having a clear understanding of the 18 skilled trades in northeast Indiana.

Fort Wayne is projecting a record number of construction projects over the next five years, necessitating a growing need for more skilled labor, the news release said.

Popular inhaler back after 7-year hiatus

A new version of the once-popular asthma inhaler Primatene Mist will soon return to U.S. stores.

The Food and Drug Administration approved the over-the-counter aerosol inhaler late Wednesday. It's for temporary relief of mild, intermittent asthma symptoms in people ages 12 and up.

The original Primatene Mist was discontinued seven years ago because the inhaler's ozone-depleting propellant had been banned. That version had been marketed for half a century, including in memorable TV ads.

The new product developed by Amphastar Pharmaceuticals uses a safer propellant. The inhaler will cost about $25 and contain 160 doses. It should be available by the end of the year.